Ads
related to: latest research on lupus
Search results
Results from the WOW.Com Content Network
The alliance is a private funder of lupus research and contributed grant funding to Rao’s study. ... The new study hints at the possibility of better treatments in the future, which could take ...
The Lupus Research Alliance (LRA) is an American voluntary health organization based in New York City whose mission is to find better treatments and ultimately prevent and cure systemic lupus erythematosus (SLE or lupus), a debilitating autoimmune disease, through supporting medical research. The organization was born from the merger of three ...
The organization works daily with the United States Congress, federal government agencies and state legislatures to make biomedical research and innovation for lupus a priority. LFA's activists successfully stimulated more than $90 million in new funding for lupus research and education programs since 2004.
Recent research has found an association between certain people with lupus (especially those with lupus nephritis) and an impairment in degrading neutrophil extracellular traps (NETs). These were due to DNAse1 inhibiting factors, or NET protecting factors in people's serum, rather than abnormalities in the DNAse1 itself. [93]
George Tsokos was born on the Mediterranean island of Evia, Greece. [4] He completed medical school at the University of Athens School of Health Sciences in 1975. [4] [5] He then finished his medical internship at Laiko General Hospital in Athens, Greece. [5]
Daniel Jeffrey Wallace (born October 27, 1949) is an American rheumatologist, clinical professor, author, and fellow. [1] Wallace has published 500 peer reviewed publications, 9 textbooks, and 28 book chapters on topics such as lupus, Sjögren syndrome, osteoarthritis, and fibromyalgia. [2]
Belimumab is primarily used in people with systemic lupus erythematosus. When it was introduced in 2011, it was the first new drug approved to treat lupus in 56 years. [8] Sales rose to $31.2 million in the first quarter of 2012. [37] The total cost for the first year of treatment with belimumab is $28,000. [38]
James was subsequently appointed the Lou Kerr Chair for Biomedical Research in 2004 and focused on understanding systemic rheumatic diseases such as systemic lupus erythematosus, scleroderma, and granulomatosis with polyangiitis. [3] In 2007, James was presented with the Edmund L. Dubois Memorial Achievement Award for her work on Lupus. [8]
Ads
related to: latest research on lupus